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Methotrexate (MTX) has been used in the treatment of 
psoriasis and other dermatological diseases for more 
than 50 years. However, there is limited evidence re-
garding its effect, dose and monitoring, and a lack of 
consensus regarding how the drug should be used in 
daily practice. Although the use of MTX is governed by 
guidelines, such as the European S3-Guidelines and 
the National Institute for Health and Care Excellence 
(NICE) guideline, it is important to discuss and adjust 
these guidelines to national standards. An expert mee-
ting was held in Denmark at the end of 2014, in order 
to reach consensus regarding the use of MTX in der-
matological practice in Denmark. Participants included 
dermatologists, hepatologists, paediatricians, clinical 
biochemists and a rheumatologist. Topics discussed 
were: liver disease monitoring, teratogenic effects of 
MTX, risk of cancer, and use of MTX in children. We 
report here the conclusions of this expert meeting re-
garding use of MTX in dermatological practice.
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Methotrexate (MTX) is a folic acid antagonist that was first used in the treatment of acute leukaemia 
in the early 1950s and subsequently for the treatment of 
solid tumours. Low-dose MTX has also been used suc-
cessfully for the treatment of rheumatoid arthritis and 
psoriasis; and over the past 25 years, MTX has become 
the standard of care in the treatment of these 2 diseases 
(1–3). The effect of MTX was originally described 
as anti-proliferative, as the drug induces inhibition of 
purine, methionine and thymidylate synthesis, and the-
reby inhibits DNA synthesis. MTX is transported into 
the cells by either a folate carrier or by passive diffusion, 
and is polyglutamated once inside the cells (4). Whereas 
MTX has a half-life of 5–8 h, the MTX polyglutamates 
are retained in cells and tissues for several weeks or 
months (5). It was suggested that low-dose MTX treat-
ment, e.g. the doses used in psoriasis, may also have 
anti-inflammatory effects, including increased adenosine 
levels, and MTX has been shown to modulate immune 
cells and to decrease the level of tumour necrosis factor 
alpha (TNFα), among other effects (3, 6).
DERMATOLOGICAL USE OF METHOTREXATE
MTX has been used in the treatment of moderate-to-
severe psoriasis for many years; yet, the first randomized 
controlled trials were not performed until 2003. These 
studies compared MTX with cyclosporine (7, 8). MTX 
was later compared with different biologics in other 
randomized controlled trials (9–11). Even so, evidence 
for its effect remains limited. Yet, MTX is used for the 
treatment of a wide range of dermatological disorders, 
including pityriasis rubra pilaris, atopic dermatitis, chro-
nic urticaria, pityriasis lichenoides, blistering disorders, 
cutaneous lupus erythematosus, localized scleroderma, 
vasculitis, cutaneous sarcoidosis, dermatomyositis and 
granuloma annulare (6). This report focuses on expe-
rience with MTX in the treatment of psoriasis. 
For dermatological indications, MTX is used in low 
doses compared with those used in oncology. No studies 
have established the best starting or maintaining dose for 
dermatological indications (12), although a few studies 
have compared different doses of MTX in the treatment 
of psoriasis (13, 14). The general recommendation in 
psoriasis is to start at 5–15 mg once weekly, with dose 
escalation up to 25–30 mg weekly, depending on the clini-
cal response (15, 16). The doses of MTX used for other 
dermatological diseases are similar to those used in pso-
riasis (6). Caution is recommended when treating elderly 
patients and patients with impaired kidney function (15). 
According to the National Institute for Health and Care 
Excellence (NICE) guideline, the maximum treatment 
response is usually seen 16–24 weeks after treatment 
initiation, although maximal effect will occasionally 
be reached within 8–12 weeks of treatment with 15 mg 
weekly doses (16). Both the PASI75, which is equal to 
a 75% reduction in the skin manifestation of psoriasis, 
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and patients’ quality of life improve significantly after 
treatment with MTX (17). In a randomized controlled 
trial, 62% of patients reached a PASI50 after 16 weeks 
of treatment, whereas 36% reached a PASI75. However, 
due to a low MTX starting dose (7.5 mg), these numbers 
are likely to be underestimated (9). This is supported by 
retrospective studies in which 40% and 62% of the pa-
tients achieved a PASI75 after 12 and 24 weeks of MTX 
treatment, respectively (18). In Denmark, it is usually 
recommended to evaluate the effect after 12 weeks of 
psoriasis treatment with the maximum tolerated dose of 
MTX (17).
In dermatology, MTX is administered orally or as a 
subcutaneous injection. In general, the oral administra-
tion route is the first choice owing to its simplicity and 
lower price. However, if there is lack of efficacy or unac-
ceptable side-effects, it is recommended to change the 
administration route to subcutaneous injection, which can 
increase the efficacy and tolerability (19, 20). 
Some of the most common side-effects of low-dose 
MTX, such as nausea, anorexia, fatigue and malaise, 
are very inconvenient for the patient, although not 
dangerous. These side-effects are dose-dependent and 
usually occur at initiation of therapy (6), and they may 
be reduced by folic acid supplementation (21). MTX can 
cause haematopoietic suppression, and haematopoietic 
biochemical monitoring is therefore recommended 
during treatment. MTX can also lead to pancytopaenia; 
however, this is a rare side-effect at the low-level doses 
used in dermatological diseases (22). The ability of 
MTX to induce liver toxicity is an important side-effect 
discussed in detail below. 
Even though the efficacy of MTX is lower than the 
biological therapies used in psoriasis, MTX is the first-
line systemic treatment for psoriasis in Denmark owing 
to its cost-effectiveness and the extensive experience in 
the use of this drug accrued over many years (23, 24). 
MTX is therefore used very frequently in dermatological 
settings; however, national guidelines on how to monitor 
MTX treatment are lacking. The aim of this paper is to 
provide recommendations regarding the use of MTX in 
a dermatological setting. Recommendations regarding 
the indication, dose and laboratory tests are summarized 
in Table I (15). 
METHOTREXATE AND LIVER MONITORING
MTX has been recognized as a hepatotoxic drug, which 
may limit its therapeutic use (25). Based on the lite-
rature and the discussion at our meeting, we suggest 
the approach summarized in Fig. 1 before and during 
treatment with MTX. Briefly, before treatment, liver 
enzymes and procollagen III aminopeptide (PIIINP) 
are tested; and if baseline values are elevated, fibroscan 
or change to another treatment is recommended. After 
treatment initiation, alanine aminotransferase (ALT) is 
measured after one week and then every second week 
for the first 2 months and then every 3 months. PIIINP is 
measured every 6 months and measurement is repeated 
within weeks if levels are elevated compared with base-
line values. Further control is needed (Fig. 1) if ALT is 
increased by more than 1.5-fold or if PIIINP is elevated 
in 3 successive samples and cannot be explained by, for 
example, psoriatic arthritis.
The pathogenesis of MTX hepatotoxicity includes 
hepatic folate depletion by MTX. Folate supplementation 
therefore results in a marked reduction in hepatotoxicity 
(26). In addition, polymorphisms in the gene encoding 
Table I. Recommendations regarding use of methotrexate (MTX)
Indication
Dose (consensus-based as per the 
Danish expert meeting)
Pre-treatment laboratory 
control Laboratory test during treatment
Moderate-to-severe psoriasis
Involvement at high-impact sites 
(face or hands)
Insufficient phototherapy or topical 
treatment 
*Use of MTX in other dermatological 
diseases is off label
Initial dose 15 mg/week increasing to a 
maximum of 25 mg/week
Reduced doses is recommended to 
elderly (10 mg/week) and those with 
renal impairment or bone marrow 
dysfunction (2.5–5 mg/week)
*5 mg folic acid supplementation is 
recommended a minimum of 24 h after 
MTX intake
Blood count
Liver enzymes
Kidney function
PIIINP
Consider: 
Pregnancy test 
HIV
Hepatitis B and C
T-spot
Blood count
Liver enzymes
Kidney function
PIIINP
(See additional information in Fig. 1) 
*As MTX is known to induce a temporary ALT 
elevation, a blood test should be performed 4–6 
days after MTX intake
Absolute contraindication Relative contraindications Vaccines Drug interaction 
Severe infections 
Severe liver disease 
Renal failure 
Conception woman¤/breastfeeding 
Alcohol abuse 
Bone marrow dysfunction/
haematological changes
Immunodeficiency 
Acute peptic ulcer 
Significantly reduced lung function 
¤Consider a 3-month paternal MTX-
free interval prior to conception
Kidney or liver disorders Old age 
Ulcerative colitis 
History of hepatitis 
Lack of compliance 
Active desire to have a child for women 
of childbearing age 
Gastritis 
Congestive heart failure 
*The total alcohol intake during 
treatment should be limited to 3–7 units 
per week
Live vaccines are not 
recommended during treatment
Annual influenza vaccination 
is recommended (may be less 
effective)
Consider hepatitis A and B 
vaccination before initiating 
treatment
Increased hepatotoxicity 
(ethanol, leflunomide, retinoids, tetracyclines)
Decreased renal elimination of MTX 
(colchicines, ciclosporin, NSAID, penicillin, pro-
benecid, salicylates, sulfonamides)
 
Increased risk of bone marrow and gastrointestinal 
toxicity 
(chloramphenicol, co-trimoxazole, cytostatic agents, 
ethanol, NSAID, pyrimethamine, sulfonamides)
Interaction with plasma protein binding 
(barbiturates, co-trimoxazole, phenytoin, 
probenecid, NSAID, sulfonamides) 
NSAID: non-steroidal anti-inflammatory drugs.
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the MTHFR enzyme have been related to low-dose 
MTX-induced hepatotoxicity (27). The pathological 
changes in the liver following MTX are characterized by 
fat infiltration with subsequent inflammation and fibrosis 
and potentially development of cirrhosis. A number of 
risk factors associated with liver steatosis, inflammation 
and fibrosis may increase the risk of MTX-induced liver 
toxicity (Table II). These risk factors include obesity, 
dyslipidaemia and diabetes as part of the metabolic 
syndrome and are strongly associated with non-alcoholic 
fatty liver disease (NAFLD) including steatohepatitis 
(NASH) (28). Furthermore, excessive alcohol intake 
and other hepatotoxic drugs, e.g. non-steroidal anti-
inflammatory drugs (NSAIDs), are important risk factors. 
The incidence and prevalence of MTX toxicity is 
debated. However, there is little doubt that cumulative 
doses are associated with hepatotoxicity. In older studies, 
a worsening on Roenigk’s 5-grade histological classifica-
tion scale was observed in 28% of patients; patients had a 
7% risk of progressing at least one histological grade for 
each gram of MTX taken. The overall incidence of ad-
vanced pathological changes ascertained in liver biopsies 
(grades IIIB or IV) was 5% (29). In a recent meta-analysis 
of observational studies, a 22% increased risk of “any 
fibrosis” on biopsy was reported following MTX therapy. 
In this meta-analysis, the cumulative dose and duration of 
MTX therapy was not associated with biopsy-
verified fibrosis or cirrhosis. Recent data also 
show that the risk of cirrhosis development 
with end-stage liver disease is quite limited, as 
determined by the very low number of patients 
listed for liver transplantation (30). 
Liver biopsy is the gold standard for assess-
ment of the severity of any liver disease, e.g. 
NASH or alcoholic liver disease with fibrosis, 
before MTX treatment is initiated, and may 
also be used during MTX treatment. However, 
performing a liver biopsy is associated with 
increased morbidity and mortality due to the 
risk of bleeding (31), and surrogate markers 
for liver disease are therefore often used. Most 
often, liver injury is assessed via the liver 
enzyme ALT, which is elevated in 7.5–26% 
of all patients treated with MTX depending 
on the cut-off level used (32). However, more 
specific methods are needed, in order to limit 
the number of liver biopsies and to evaluate 
the risk of liver fibrosis. 
The PIIINP has been used in the assessment of liver 
fibrosis, as fibrogenesis results in the release of certain 
extracellular matrix proteins, including PIIINP, into the 
bloodstream. PIIINP is a molecule that derives from type 
III procollagen biosynthesis (33). Changes in PIIINP 
levels are not specific to a particular disease, but reflect 
the involvement and altered metabolism of type III colla-
gen depending on the activity and the extent of the tissue 
involved. Levels are high in children and adolescents as a 
result of physiological growth (34). In conditions where 
accumulation and/or degradation of connective tissue 
takes place, PIIINP levels are increased; and interpreta-
tion of the individual PIIINP values can be challenging 
because active joint involvement, smoking and other 
factors may lead to an increase in PIIINP levels that is 
unrelated to hepatic fibrosis (15). PIIINP is therefore less 
useful for monitoring of patients with psoriatic arthritis 
(35, 36), and therefore there is a need for further deve-
lopment of biomarkers. 
A meta-analysis on assessments of liver toxicity in 
MTX-treated patients with psoriasis calculated that 
PIIINP had a sensitivity of 77% and a specificity of 92%. 
Thus, PIIINP can be expected to have a good negative 
predictive value when the prevalence of severe fibrosis is 
expected to be low (37). In general, the risk of develop-
ment of hepatic fibrosis is minimal if serial measurements 
of PIIINP are normal (35, 36).
The Enhanced Liver Fibrosis test (ELF™, Siemens 
Healthcare Diagnostic Inc., Tarrytown, NY, USA) was 
introduced recently as a non-invasive test of liver fibrosis. 
An ELF score is calculated using an algorithm based on 
analysis of PIIINP, hyaluronic acid and tissue inhibitor 
of matrix metalloproteinase-1 (TIMP-1). Studies indicate 
that the ELF test can be used to detect fibrosis in chronic 
Fig. 1. Algorithm for methotrexate (MTX) treatment and monitoring of liver 
toxicity and fibrosis. #Reference Limit (RL), method-specific. *Primary use of alanine 
aminotransferase (ALT) to monitor liver toxicity if procollagen III aminopeptide (PIIINP) 
is elevated due to, for example, psoriatic arthritis.
Table II. Risk factors for methotrexate (MTX)-induced liver toxicity
• Risk factors for liver disease
• Metabolic syndrome (obesity, hyperlipidaemia, hypertension, type 2 
diabetes mellitus)
• Non-alcoholic fatty liver (NAFL) and steatohepatitis (NASH)
• Alcohol intake above recommended limits
• Chronic viral hepatitis B and C
• Other hepatotoxic drugs, e.g. non-steroidal anti-inflammatory drugs
• Haemochromatosis
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liver diseases, such as primary biliary cirrhosis, NAFLD 
and chronic hepatitis C infection, and that the score has 
a higher diagnostic value than the individual tests alone 
(38–41). At present, only a single study has studied ELF 
as a non-invasive marker of MTX-induced hepatotoxicity 
(42). From this study it was concluded that ELF may be 
at least equivalent or possibly superior to PIIINP. The 
PIIINP assay that is part of the ELF test is different from 
the Orion Ercopharm PIIINP radioimmunoassay, which 
has been studied extensively. The Siemens PIIINP from 
the ELF test gives higher values due to a different stan-
dardization, but the values compare relatively well (43). 
During the past decade other non-invasive tools, 
such as transient elastography and fibro test to monitor 
hepatotoxicity in MTX-treated patients with psoriasis, 
have been introduced, but large prospective studies are 
needed (44). Also fibroscan for liver fibrosis have become 
available and have proven effective in other fibrotic liver 
diseases (45). This has been evaluated in a few trials stu-
dying MTX-induced liver toxicity. In a study of patients 
with psoriasis only, the median fibroscan value was 6.4 
kPa (range 3.3–18.4 kPa) and the fibroscan correctly 
identified 88% of the patients without significant liver 
fibrosis based on a liver biopsy (METAVIR score < F2, 
fibroscan ≤ 7.1 kPa) (46). However, fibroscan has yet 
to be validated for use in MTX-treated patients. Other 
scanning modalities are required and better biomarkers 
for liver disease severity and progression are needed.
Conclusion: Liver monitoring
MTX hepatotoxicity remains a clinical challenge in 
patients with psoriasis, and monitoring is important. 
The algorithm shown in Fig. 1 is recommended, and 
the importance of recognizing the increased risk of liver 
fibrosis in at-risk patient groups (Table II) is stressed. 
New imaging modalities and biomarkers for liver fibrosis 
provide the basis for non-invasive assessment of MTX 
liver toxicity.These tools will reduce the need for liver 
biopsies during follow-up of patients who receive MTX 
treatment.
METHOTREXATE AND PREGNANCY
MTX is embryotoxic in humans and animals (47). Dif-
ferent forms of embryopathies have been described after 
exposure during gestational weeks 5–8. The most severe 
malformation is “aminopterin syndrome” consisting of 
multiple central nervous system (CNS), skeletal and 
cardiac abnormalities. New prospective studies in pa-
tients with rheumatoid arthritis have shown no increase 
in spontaneous abortion or in congenital malformations 
when MTX was given 6–0 months before conception. 
However, when given at doses of 10–20 mg/week during 
the first trimester, a high rate of spontaneous abortion 
(20–40%) and a slight increase in congenital malforma-
tions with a variety of single and combined defects, as 
well as cardiac defects at high doses have been observed 
(48). Therefore, MTX must be discontinued in women 
1–3 months before a planned pregnancy. Folic acid supp-
lementation should be given to all patients of fertile age 
who are receiving MTX treatment, and supplementation 
should be continued during the first trimester even after 
withdrawal of MTX before a planned pregnancy.
In general, MTX at doses between 5 and 25 mg/week 
do not impair spermatogenesis. Several recent cohort 
studies investigating the outcome of pregnancies fathered 
by men who had taken MTX within 3 months before 
conception have failed to show any increase in congenital 
malformations in their children (49). A 3-month paternal 
MTX-free interval prior to conception does not appear 
to be necessary (50, 51). However, the drug information 
leaflet and the European S3-Guidelines still recommend 
a 3-month MTX-free interval before conception (15). 
The need for this interval should be considered on an 
individual basis. 
Conclusion: Pregnancy and methotrexate
Low-dose MTX given for treatment of skin diseases 
can induce congenital malformations if administered 
during gestational weeks 5–8. MTX treatment during 
the first trimester may increase the rate of spontaneous 
abortion. MTX treatment must therefore be discontinued 
3 months prior to planned pregnancy in females. There 
is no evidence to indicate that male fertility is impaired 
by standard doses of MTX; nor is there any evidence to 
support an increased rate of birth defects after paternal 
low-dose MTX intake around conception. However, 
the European S3-Guidelines still recommend a 3-month 
paternal MTX-free interval prior to conception, and it 
should therefore be considered on an individual basis. 
METHOTREXATE AND CANCER
The risk of cancer in patients with immune-mediated 
inflammatory diseases has been debated in recent years. 
Chronic inflammation may have a pro-tumourigenic 
effect and immunosuppressive treatment may increase 
the risk, but, at the same time, inflammatory cells and 
cytokines may have an anti-tumour effect. 
Studies of patients with psoriasis have shown an in-
creased risk of some solid cancers, especially cancers 
related to the respiratory tract, urinary tract and liver 
cancer (52). These are cancers that have been related 
to alcohol consumption and smoking habits, which are 
more common in patients with psoriasis (53). The risk of 
lymphomas has been shown to be slightly increased in 
patients with psoriasis (54). Patients with psoriasis also 
have an increased risk of non-melanoma skin cancer, 
especially squamous cell carcinomas (SCC) (55). The 
increase in non-melanoma skin cancer has been asso-
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ciated with previous use of ultraviolet (UV) treatment, 
especially psoralen plus ultraviolet A (PUVA), but im-
munosuppressive treatment, such as cyclosporine, may 
also increase the risk (56–58). Furthermore, MTX has 
been associated with an increased cancer risk in 1 study 
(56). Whether MTX treatment alone increases the risk 
of cancer in patients with psoriasis is debated. There 
have been some cases of lymphoproliferative diseases 
in patients treated with MTX; however, most of these 
patients had rheumatoid arthritis, and only a few cases 
have been reported in patients with psoriasis (59). 
MTX is also used for treatment of many types of can-
cers and, in line with acitretin, MTX is recommended 
as treatment for moderate-to-severe psoriasis in patients 
with a history of previous cancer. 
One study in patients with psoriasis who had pre-
viously been treated with PUVA and subsequently with 
MTX showed an increased risk of SCC (58). No studies 
have found an increased risk of non-melanoma skin 
cancer following a combination of UVB treatment and 
MTX. However, it is generally recommended to routinely 
screen the skin for skin cancer during treatment with im-
munosuppressive drugs, including MTX. This should be 
done at least once a year. 
Conclusion: Cancer and methotrexate
MTX clearly exhibits anti-tumourigenic effects, as 
demonstrated by its common use in treating different 
malignancies. However, based on the literature, it is not 
possible to conclude whether treatment with low-dose 
MTX in patients with psoriasis exhibits pro-tumourigenic 
effects. Owing to many years of experience with MTX 
treatment (compared with other treatments), we do not list 
previous cancer as a relative contraindication for MTX 
treatment in patients with psoriasis. However, patients 
with psoriasis have an increased risk of non-melanoma 
skin cancer, and annual screening of the skin for skin 
cancer is recommended when patients are being treated 
with all immunosuppressive drugs, including MTX.
METHOTREXATE USE IN CHILDREN
The evidence for use of MTX in paediatric patients with 
psoriasis is limited to case reports and observational stu-
dies. Furthermore, MTX is not registered for paediatric 
psoriasis, and thus has to be used off-label. In general, 
a good clinical effect is demonstrated. One randomized 
controlled study comparing adalimumab with MTX has 
been conducted; however, the data have yet to be publish-
ed (60). The MTX doses used in psoriasis are 0.2–0.4 
mg/kg/week (~6–12 mg/m2/week), although higher doses 
can be used (maximum 20 mg/week) (61, 62). 
Most evidence regarding the use of low-dose MTX 
in paediatric patients is found for rheumatic indications, 
especially juvenile idiopathic arthritis (JIA), juvenile 
dermato-myositis (JDM) and localized scleroderma (LS). 
The recommendations regarding the administration, mo-
nitoring, adverse events and long-term effect of low-dose 
MTX treatment in paediatric patients are based primarily 
on experiences from MTX treatment in JIA as no recom-
mendations have yet been published in children with 
psoriasis. In JIA, the dosage of MTX is usually 10–15 
mg/m2/week (60, 63–67). 
MTX in children may be administered orally or sub-
cutaneously. Subcutaneous administration of MTX is 
more often preferred in children because it has fewer 
side-effects and allows administration of higher doses. 
Furthermore, the bioavailability is higher and more stable 
(68). In dermatology, it is common practice to monitor 
children via blood samples prior to initiation, weekly 
for 4 weeks after treatment start and then every other 
week up to week 8. When the paediatric patient is on a 
stable dose, laboratory tests should be similar to those 
recommended for adult patients (Table I) (69). However, 
use of PIIINP is difficult in paediatric patients because 
it increases during growth (70). Similar to adults, the 
adverse events most commonly associated with low-dose 
MTX treatment are nausea, vomiting and elevated liver 
enzymes (60). As in the treatment of adult patients, it is 
recommended to prescribe 5 mg folic acid (71). 
In general, low-dose MTX is safe both in the short 
and the long term. It has not been found to affect growth 
nor fertility, nor has it been proven to be associated with 
malignancies (60, 72). 
Conclusion: Methotrexate use in children
The evidence regarding the use and safety of low-dose 
MTX in paediatric patients is limited and based mostly 
on JIA studies. In general, doses of 0.2–0.4 mg/kg/week 
for the treatment of psoriasis and close monitoring are 
recommended in paediatric patients with psoriasis. 
Treat ment with low-dose MTX is effective and seems 
not to affect growth or fertility or to be associated with 
an increased risk of malignancies. 
CONCLUSION 
This report was based on an expert meeting. It is hoped 
that it will provide further consensus regarding the 
use and monitoring of MTX treatment in patients with 
psoriasis in Denmark and other countries. In general, 
the recommendations given above are in line with the 
European S3-Guidelines.
The authors declare no conflicts of interest.
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